retatrutide phase 2 trial new england journal of medicine Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a VisualAbstract: Retatrutide reduces body weight

(June 2026)

If a DXA scan is not accessible, bioelectrical impedance analysis (BIA) available in many smart scales and at gyms provides a reasonable estimate

Theoretical pharmacological analysis can identify potential interaction points

More recent agents include dual agonists such as tirzepatide, which activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors and produces even greater weight loss

O que o medicamento A molcula pertence mesma famlia de remdios que popularizou o Ozempic, o Wegovy e o Mounjaro, mas com uma diferena de mecanismo: enquanto a semaglutida age sobre o hormnio GLP-1 e a tirzepatida combina GLP-1 e GIP, a retatrutida atua sobre trs receptores ao mesmo tempo, somando o glucagon

Retatrutide isnt FDA-approved yet, and some estimates suggest late 2026 to early 2027 for that